The Law Offices of Frank R. Cruz Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
The Law Offices of Frank R. Cruz has initiated an investigation into potential breaches of fiduciary duty by the board of directors of RxSight, Inc. (RXST) following significant declines in the company's Q2 2025 financial results and a lowered full-year guidance. This investigation comes after RxSight's stock price dropped by 37.8% on July 9, 2025, due to "adoption challenges" impacting sales. Shareholders who purchased RxSight shares before November 2023 are encouraged to contact the law firm for further discussion.
BofA cuts RxSight stock price target on weak Q2 sales, guidance
BofA Securities has lowered its price target for RxSight Inc. (RXST) to $6.50 from $8.00, maintaining an Underperform rating, due to weak preliminary second-quarter sales and a reduced 2026 guidance. The company reported preliminary Q2 sales of $27 million, below estimates, and lowered its full-year guidance due to competitive pressures and lower consumer sentiment, despite an announced strategic collaboration with ALC. RxSight's stock is currently trading at $5.09, and InvestingPro suggests it may be undervalued.
RxSight Inc. (RXST) PT Lowered to $6.50 at BofA Securities
BofA Securities analyst Craig Bijou has lowered the price target for RxSight Inc. (NASDAQ: RXST) to $6.50 from $8.00. The analyst maintained their rating on the stock. The article is premium content, requiring a subscription to read further details.
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight
Alcon and RxSight have partnered to co-develop presbyopia-correcting intraocular lenses (PCIOLs) for cataract patients, with Alcon investing up to $200 million. This collaboration aims to combine RxSight's light-adjustable technology with Alcon's optical designs to create customizable lenses, giving surgeons more flexibility in patient outcomes. Alcon will lead global commercialization, while RxSight will receive royalties on sales.
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs
Alcon and RxSight have announced a non-exclusive collaboration to develop adjustable presbyopia-correcting intraocular lenses (PCIOLs). RxSight will receive an upfront payment of $60 million, with potential for an additional $140 million as development and regulatory milestones are met. Alcon will handle global commercialization, while RxSight will be responsible for development and manufacturing and will receive royalties on net sales.
RxSight reports Q2 revenue of $32-34M, cuts 2026 sales outlook
RxSight Inc. announced preliminary second-quarter revenue of $32 million to $34 million, including contributions from a collaboration with Alcon, but revised its full-year 2026 revenue guidance downward to $140 million to $160 million due to commercial headwinds. Despite a recent stock jump, the company's shares are significantly below last year's levels. RxSight plans increased investments in its sales force and next-generation Light Adjustable Lens products.
RxSight (NASDAQ: RXST) cuts 2026 sales outlook but lifts margin view
RxSight (NASDAQ: RXST) announced preliminary Q2 2026 results and updated its full-year 2026 outlook, cutting its sales guidance but raising its gross margin forecast. The company expects Q2 revenue of $32–$34 million, including $5–$7 million from a new collaboration with Alcon, and anticipates full-year 2026 total revenue of $140–$160 million, with a higher gross margin of 73%–75%. Despite facing commercial headwinds and increased operating expenses due to accelerated investments, RxSight maintains a strong liquidity position of approximately $209 million.
Press Release: RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
RxSight, Inc. announced preliminary second-quarter 2026 financial results, with revenue expected to be between $22.5 million and $23.5 million, marking a 30% to 36% increase year-over-year. The company also provided updates on its product pipeline, including progress on its next-generation Light Adjustable Lens and related devices. This announcement follows a recent strategic collaboration agreement, which is expected to support future growth and product development.
RxSight, Inc. Announces Preliminary Second Quarter
RxSight, Inc. announced preliminary second-quarter 2026 financial results, including expected revenue of $32 to $34 million, which includes $5 to $7 million from its strategic collaboration with Alcon. The company also provided updates on its product pipeline, featuring next-generation Light Adjustable Technology™ lenses, and updated its full-year 2026 guidance to $140-$160 million in revenue. Despite commercial headwinds, RxSight aims to accelerate investments in its sales force and commercial capabilities, leveraging its technology and balance sheet for future growth.
RxSight sees Q2 sales of $27M as Alcon deal adds revenue
RxSight (NASDAQ: RXST) expects preliminary Q2 2026 revenue of $32–$34 million, including $5–$7 million from its collaboration with Alcon. Product sales reached approximately $27 million, with 24,917 Light Adjustable Lens units sold. The company also updated its 2026 revenue guidance to $140–$160 million and highlighted new products and the Alcon collaboration for light-adjustable presbyopia-correcting intraocular lenses.
Join Class Action to Recover Losses From RxSight, Inc. (RXST) - Contact Levi & Korsinsky Before September 22, 2025
Levi & Korsinsky LLP has announced a class action securities lawsuit against RxSight, Inc. (NASDAQ: RXST) for shareholders who suffered losses between May 7, 2024, and July 8, 2025. The lawsuit alleges that RxSight made misleading statements regarding "adoption challenges" and overstated product demand, leading to a failure to meet financial guidance. Shareholders are encouraged to contact the firm before September 22, 2025, to learn about their rights to potentially recover losses.
RxSight, Inc. Financial Disclosures & SEC Filings
This document provides a comprehensive list of RxSight, Inc.'s financial disclosures and SEC filings, including quarterly and annual reports, earnings releases, and event transcripts from various healthcare conferences. It spans from Q1 FY2025 to Q1 FY2026, offering insights into the company's financial performance, operational updates, and strategic focus on adjustable lens technology, premium IOL growth, and global expansion. The disclosures highlight revenue trends, gross margin changes, and market strategies for their Light Adjustable Lens (LAL) technology.
Did RxSight, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of RxSight, Inc. (RXST) breached their fiduciary duties to shareholders. Long-term shareholders of RxSight are encouraged to contact the firm to discuss potential corporate governance reforms, the return of funds to the company, or other forms of relief. The firm emphasizes that shareholder involvement can improve company oversight and enhance shareholder value.
Law firm investigates RxSight officers for possible breach of duties to shareholders.
Halper Sadeh LLC is investigating whether officers and directors of RxSight, Inc. breached their fiduciary duties to shareholders. The law firm is offering free consultations to long-term shareholders who may be eligible for corporate reforms, financial awards, or other relief. Shareholders are urged to act quickly due to potential time limitations on claims.
Bronstein, Gewirtz & Grossman, LLC Encourages RxSight, Inc. (RXST) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ: RXST) securities. The investigation centers on whether RxSight and its officers engaged in corporate wrongdoing, particularly for investors who bought shares before November 7, 2024. The firm encourages affected shareholders to contact them to assist in the investigation, operating on a contingency fee basis.
RxSight, Inc.(NasdaqGM: RXST) added to Russell Microcap Index
RxSight, Inc. (NasdaqGM: RXST) announced its inclusion in the Russell Microcap Index, effective June 29, 2026, and also its addition to the Russell Microcap Value Benchmark Index CI. This news comes alongside several other Russell index adjustments for the company on the same day, including its addition to the Russell 2000 Value Benchmark CI and its removal from Growth-focused benchmarks. The company, a medical technology firm specializing in customized vision solutions for cataract patients, maintains an average target price of $8.786 from analysts.
Class Action Alert: Levi & Korsinsky Reminds RxSight, Inc. (RXST) Investors of September 22, 2025 Deadline
Levi & Korsinsky reminds investors of RxSight, Inc. (RXST) about a class action lawsuit deadline on September 22, 2025. The lawsuit alleges that RxSight made false statements and concealed "adoption challenges" and overstated demand, leading to declines in sales and utilization between May 7, 2024, and July 8, 2025. Investors who suffered losses during this period are encouraged to learn about their rights to seek recovery.
RxSight, Inc.(NasdaqGM: RXST) added to Russell 2000 Value Benchmark
RxSight, Inc. (NasdaqGM: RXST) has been added to the Russell 2000 Value Benchmark Index, effective June 29, 2026, at 11:47 am EDT, according to an announcement published by MarketScreener. This inclusion comes alongside other recent index adjustments for the company, including its addition to the Russell Microcap Value Benchmark Index and subsequent removal from the Russell 2000 Growth and Russell 3000E Growth Benchmarks.
Liquidity Mapping Around (RXST) Price Events
Quantitative Research Desk has provided an analysis of Rxsight Inc. (NASDAQ: RXST), highlighting a strong near and mid-term sentiment but a weak long-term outlook. The analysis identifies a significant 197.0:1 risk-reward setup, targeting a 43.2% gain against 0.2% risk, and outlines specific institutional trading strategies for different risk profiles. The report leverages AI models to generate real-time signals, including entry and exit points, support, and resistance levels across various time horizons.
RxSight, Inc. (RXST) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline
Levi & Korsinsky LLP announced a class action securities lawsuit against RxSight, Inc. (NASDAQ:RXST) for alleged securities fraud between November 7, 2024, and July 8, 2025. The lawsuit claims RxSight made false statements and concealed "adoption challenges" and structural issues leading to declining sales and an overstatement of product demand. Investors who suffered losses can join the lawsuit by the September 22, 2025 deadline to seek recovery.
Lost Money on RxSight, Inc. (RXST)? Contact Levi & Korsinsky Before September 22, 2025 to Join Class Action
Levi & Korsinsky LLP has filed a class action securities lawsuit against RxSight, Inc. (NASDAQ:RXST) on behalf of investors who suffered losses between November 7, 2024, and July 8, 2025. The lawsuit alleges that RxSight made false statements and concealed "adoption challenges" and overstated demand, leading to the company being unlikely to meet its fiscal year 2025 financial guidance. Shareholders are encouraged to contact the firm before September 22, 2025, to learn about their rights to potentially recover losses.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ: RXST). The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. Investors who bought RxSight securities before November 7, 2024, and still hold them, are encouraged to contact the firm for more information and to assist in the investigation.
RXST INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against RxSight, Inc. (NASDAQ:RXST) on behalf of investors who purchased securities between November 7, 2024, and July 8, 2025. The lawsuit alleges that RxSight made misleading statements regarding "adoption challenges" and overstated product demand, implying the company would not meet its 2025 financial guidance. Investors who suffered losses are encouraged to contact the firm to potentially serve as lead plaintiff by September 22, 2025.
RXST Forecast — Price Target — Prediction for 2027
This article provides a detailed forecast and financial overview for RxSight, Inc. (RXST), including analyst price targets, stock performance, and key financial metrics. It highlights the current stock price, volatility, market capitalization, and upcoming earnings report, offering insights into its past performance and future expectations.
RxSight, Inc. Actuals & Estimates (BOATS:RXST)
This article provides an overview of RxSight, Inc. (RXST) stock performance, financial actuals and estimates. It covers analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net income, and EBITDA. The company does not pay dividends and has 461 employees as of the article's publication date.
RxSight, Inc. Actuals & Estimates (NASDAQ:RXST)
This article provides an overview of RxSight, Inc. (NASDAQ:RXST) stock performance, financial estimates, and frequently asked questions for investors. It details the current stock price, recent changes, analyst forecasts, historical highs and lows, volatility, market capitalization, and upcoming earnings report information. The content serves as a guide for understanding RXST's market position and financial health.
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Rxsight Inc (RXST), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that RXST ranks 184 out of 203 in the Healthcare Equipment & Supplies industry with an average analyst price target of $10.00. The article also includes information on anticipated revenue and EPS for upcoming quarters and analyst recommendations.
RXST SEC Filings - Rxsight, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Rxsight, Inc. (RXST) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It details the types of information found in these filings, such as operating results, sales guidance, and governance matters. The site also lists recent filings with AI-generated impact and sentiment analysis.
RxSight (RXST) director Shweta Maniar receives 37,037 RSU award
RxSight, Inc. director Shweta Maniar was granted 37,037 Restricted Stock Units (RSUs) as part of her compensation, as reported in a Form 4 filing. These RSUs, valued at $0.00 per share, will vest fully on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company's next annual shareholder meeting, provided Maniar continues as an Outside Director. Following this award, Maniar directly holds a total of 55,172 shares of RxSight Common Stock.
Tamara Fountain at RxSight (RXST) receives 37,037-share RSU award
RxSight director Tamara Fountain was granted 37,037 restricted stock units (RSUs) as a compensation-related award on June 17, 2026. These RSUs, which represent one share of common stock each, will vest 100% on the earlier of the one-year anniversary of the grant date or the next annual stockholder meeting, provided she continues as an Outside Director. Following this award, Fountain directly holds 72,582 shares of RxSight common stock.
RxSight (RXST) director receives 37,037 restricted stock units in equity grant
RxSight, Inc. director Robert Keith Warner was granted 37,037 restricted stock units (RSUs) as compensation, increasing his direct holdings to 78,076 shares. These RSUs will vest annually on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholders' meeting, provided he remains an Outside Director. This transaction is a non-cash award and not an open-market purchase.
RxSight (RXST) director William J. Link granted 37,037-share stock award
RxSight director William J. Link was granted an equity award of 37,037 shares of common stock, valued at $0.00 per share, as part of his compensation. This award, structured as restricted stock units (RSUs), brings his direct holdings to 74,892 shares. The RSUs will vest 100% on the earlier of one year from the grant date (June 17, 2026) or the next annual stockholder meeting, conditional on his continued service as an Outside Director.
RxSight (RXST) director awarded 37,037 RSUs in equity compensation grant
RxSight, Inc. director Robert J. Palmisano was granted 37,037 restricted stock units (RSUs) as equity compensation, as detailed in a Form 4 SEC filing. These RSUs represent a contingent right to receive one share of common stock each and will vest fully in a single tranche. This vesting is conditional on his continued service as an Outside Director, occurring on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholders' meeting.
RxSight (RXST) director granted 30,864 RSUs vesting by next meeting
RxSight, Inc. director Raymond W. Cohen was granted 30,864 Restricted Stock Units (RSUs) on June 17, 2026, which will vest 100% on the earlier of one year from the grant date or the next annual stockholder meeting, provided he continues his service as an Outside Director. Following this award, Cohen directly holds a total of 66,532 shares/RSUs of RxSight common stock. The RSUs were granted at $0.00 per share, meaning no cash payment was required from Cohen for their acquisition.
RxSight Stockholders Back Leadership at 2026 Annual Meeting
RxSight (RXST) held its 2026 Annual Meeting of Stockholders on June 16, 2026, where shareholders re-elected directors, approved executive compensation, and ratified Ernst & Young LLP as independent auditor. This indicates strong support for the company's leadership and financial oversight. An analyst from TipRanks has a Hold rating with an $8.00 price target, while TipRanks' AI Analyst, Spark, rates RXST as Neutral due to ongoing losses, negative cash flow, and bearish technical momentum despite strong gross margins and a low-debt balance sheet.
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Rxsight Inc (RXST), listing its major institutional holders and their proportion of shares. It also breaks down shareholder types by category such as Investment Advisor and Hedge Fund, and tracks institutional shareholding changes over recent quarters. The data indicates the significant presence of institutional investors in RXST.
Rxsight Inc (RXST) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Rxsight Inc (RXST) dividend and stock split history. It indicates that Rxsight Inc has not distributed any dividends over the past five years and has no recorded stock split events. The page also includes current stock information for RXST, such as its market capitalization and price performance.
Rxsight Inc (RXST) Institutional Confidence
Rxsight Inc (RXST) has a strong institutional confidence score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This is supported by a high institutional shareholding proportion of 93.24%, which increased by 11.69% quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 804.27K shares.
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis
Rxsight Inc (RXST) has a current financial score of 6.91, ranking 126 out of 203 in the Healthcare Equipment & Supplies industry. The company's financial status is stable with average operating efficiency, but it experienced a year-over-year decrease in both revenue and net profit. Its latest quarterly revenue was $30.89M, a 18.48% decrease, and net profit saw a significant 93.94% decrease.
RxSight (RXST) investors re-elect board, approve pay and ratify Ernst & Young
RxSight, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders re-elected three Class II directors—William J. Link, Robert Warner, and Shweta Singh Maniar—to serve until the 2029 annual meeting. Investors also approved executive compensation on an advisory basis and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Approximately 80.4% of eligible shares were represented at the meeting, indicating strong stockholder participation.
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
This article reports that RxSight, Inc. (RXST) announced a diluted loss of $0.46 per share for Q3, matching the Zacks Consensus Estimate. Despite the loss, the company surpassed revenue expectations, bringing in $26.1 million against an estimated $25.92 million. RxSight's revenue also saw a significant year-over-year increase of 56.6%.
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) reported a narrower-than-expected loss in Q3, with revenue exceeding analyst estimates. The company posted a quarterly loss of $0.37 per share, an improvement from the prior year's loss, and recorded revenues of $26.87 million, significantly up year-over-year. This positive performance was in line with Zacks Consensus Estimates, showing promising growth for the company.
RxSight, Inc. Hits 52-Week Low at USD 4.93 Amidst Ongoing Struggles
RxSight, Inc. has reached a new 52-week low of USD 4.93, reflecting a significant decline over the past year and underperforming the S&P 500. The company has reported negative results for four consecutive quarters, with falling net sales and a negative return on equity indicating ongoing financial struggles. Its negative debt-to-equity ratio and lack of a dividend yield further highlight its challenging financial health.
RXST Technical Analysis & Stock Price Forecast
Rxsight Inc (RXST) currently exhibits a "Strong Sell" technical sentiment based on an aggregation of 12 technical signals, with 9 indicating sell and 3 indicating buy. The stock is trading below its 20-day, 60-day, and 200-day simple moving averages, and its MACD indicator also suggests a "Strong Sell" signal. Key support for RXST is at $5.054, with resistance at $6.569, and its RSI is in neutral territory.
RxSight Inc stock (US78419L1008): Nasdaq-listed eye-care specialist in focus after recent price weak
RxSight Inc shares (RXST) on the Nasdaq experienced a pullback in late May 2026, drawing investor attention to the ophthalmic technology group. The stock closed down 4.65% at USD 5.33 on May 29, 2026, reflecting sensitivity to sentiment around smaller medical technology issuers. The company, focused on adjustable intraocular lenses for cataract surgery, is currently without verified analyst coverage, emphasizing the importance of future disclosures for market observers.
Avoiding Lag: Real-Time Signals in (RXST) Movement
This article analyzes Rxsight Inc. (NASDAQ: RXST) using AI models, highlighting a near-term strong sentiment contrasting with persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and presents three distinct trading strategies with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26
RxSight, Inc., a company specializing in adjustable intraocular lenses for cataract surgery, will participate in the Stifel 2026 Virtual Ophthalmology Forum. The management team is scheduled for a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. The event will be webcast live and archived on RxSight's investor relations website, offering investors insights into the company's vision correction technology and future outlook.
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. announced its participation in the Stifel 2026 Virtual Ophthalmology Forum, where management will hold a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. A webcast of the presentation will be available on the company's investor relations website. RxSight specializes in ophthalmic medical devices, specifically the Light Adjustable Lens system, which allows for post-surgery vision customization for cataract patients.
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. announced its participation in the Stifel 2026 Virtual Ophthalmology Forum, where management will engage in a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. The event's webcast will be accessible via the company's investor relations website. RxSight specializes in advanced ophthalmic medical devices, notably their Light Adjustable Lens system, which allows post-surgery customization of vision for cataract patients.
RxSight management to appear at Stifel 2026 virtual eye forum May 26
RxSight, Inc. (NASDAQ: RXST) announced its management will participate in a fireside chat at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast will be available on the company's investor relations website. This event is part of RxSight's ongoing investor outreach, which has historically shown mixed reactions in stock price around similar conference appearances, earnings, and milestone announcements.
